OTC Markets OTCQB - Delayed Quote USD

Gemina Laboratories Ltd. (GLABF)

Compare
0.7735
0.0000
(0.00%)
As of April 8 at 4:00:00 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Brian Firth CEO & Director 73.96k -- --
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA CFO & Company Secretary 40.57k -- 1960
Dr. Robert Crandall Greene CTO & Director 110.52k -- --
Mr. Hugh McNaught VP of Marketing & Member of Advisory Board -- -- --
Mr. David Browning FCIM, M.Sc. Head of Productization & Director of Gemina Laboratories (UK) Limited -- -- --
Dr. Christine Buerki Ph.D. Head of Product Development -- -- --

Gemina Laboratories Ltd.

3600 Gilmore Way
Unit 302
Burnaby, BC V5G 4W8
Canada
https://www.geminalabs.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

Corporate Governance

Gemina Laboratories Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 30, 2025 at 8:00 PM UTC - June 4, 2025 at 8:00 PM UTC

Gemina Laboratories Ltd. Earnings Date

Recent Events